Caris Life Sciences Launches First Ever Molecular AI Product

Caris Life Sciences Launches First Ever Molecular AI Product

Cancer-News

1 week
34 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the launch of the newest addition to its comprehensive genomic profiling offerings, MI GPS™ (Genomic Profiling Similarity) Score. MI GPS Score is an AI driven tumor type biology similarity score that uses more than 6500 mathematical models in the machine learning algorithm to compare molecular characteristics of a patient’s tumor against Caris’ extensive database to provide new insights into the molecular subtype of cancer of unknown primary (CUP) cases, atypical clinical presentation cases, and other difficult to treat cancer cases, to help guide treatment decisions.

 

“Caris has the world’s largest and most comprehensive database of paired molecular information with clinical outcomes,” said David Spetzler, MS, MBA, Ph.D., President and Chief Scientific Officer of Caris. “We are actively employing advanced machine learning capabilities with this data set to identify unique molecular signatures that our industry-leading pathologists can use to better identify cancer subtypes and predict patient response to certain therapies.  The combination of AI and human intelligence provides the most comprehensive analysis available today to characterize a patient’s tumor.”

Read here: https://www.oncologytube.com/video/caris-life-sciences-launches-first-ever-molecular-ai-product-a-clinical-genomic-profiling-similarity-score

Up Next Autoplay
Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020
Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020
Category: News
2 Views
Cancer-News 15 hours
Alternative Pain-Control Strategy Reduces Need for Opioids in Patients with Head and Neck Cancer
Alternative Pain-Control Strategy Reduces Need for Opioids in Patients with Head and Neck Cancer
Category: Head and Neck Cancers
2 Views
Cancer-News 1 day
JAVELIN Study: How Does This Affect Clinicians?
JAVELIN Study: How Does This Affect Clinicians?
Category: Urology
2 Views
Cancer-News 2 days
What happened to patients with progression of disease?
What happened to patients with progression of disease?
Category: Urology
3 Views
Cancer-News 2 days
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Category: Urology
12 Views
Cancer-News 2 days
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Category: Prostate Cancer
1 Views
Cancer-News 5 days
The Impact of Therapy with External-Beam Radiotherapy
The Impact of Therapy with External-Beam Radiotherapy
Category: Prostate Cancer
1 Views
Cancer-News 5 days
Is there a correlation between the target volume of radiation?
Is there a correlation between the target volume of radiation?
Category: Prostate Cancer
0 Views
Cancer-News 5 days
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
Category: Pancreatic Cancer
2 Views
Cancer-News 5 days
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Category: Prostate Cancer
11 Views
Cancer-News 5 days